Deutsche $17 Target- Says ACHN Drug Will Be 15% Less Costly Than GILD (post)
Should Achillion Pharma (ACHN) Be In Your Portfolio Now?
By Zacks Research Staff 2 minutes ago
Deutsche Bank Upgrades ACHN to “Buy”
As of August 18th, Deutsche Bank’s Alethia Young determined a price target of $17.00, and upgraded the rating from a “neutral” to a “buy”. According to Street Insider, Deutsche Bank has estimated that the Hepatitis C Virus treatment will cost around 5% less than GILD’s Sovaldi treatmen